Notably, they showed that tumor burden was more significantly reduced when mice were treated with MS177 instead of with UNC6852, a PROTAC that selectively targets EED (Potjewyd et al., 2020) and therefore the PRC2 activity but not the PRC2-independent activity of EZH2. Here, EZH2 is linked to neoplasm.